Sexual dysfunction may persist after discontinuing SSRI or SNRI antidepressantsHealth Canada safety review reports on risk of persistent, worsening or new sexual dysfunction after stopping SSRI or SNRI treatment. Study: Link established between loneliness and depressive symptoms Usual doses of tramadol may cause visual and auditory hallucinations Health Canada safety review identifies new risk, particularly in people older than age 65. New prescription hypnotic for insomnia now available in Canada First marketed orexin receptor antagonist is approved for adults with difficulties in falling asleep and/or maintaining sleep. Managing people with opioid-use disorder in the emergency department Canadian Association of Emergency Physicians offers recommendations for emergency healthcare providers to help address Canada’s opioid crisis. Nonbenzodiazepine hypnotic, Lunesta (eszopiclone) now marketed in Canada Approved for short-term use in adults with difficulty falling asleep, or nocturnal or early morning awakenings. Provide families with guidance on how to reset sleep times disrupted by COVID-19 Pandemic has significantly altered normal sleep patterns for children and teenagers Scientists get closer to blood test for Alzheimer's disease The testing identified people with Alzheimer's vs. no dementia or other types of it with accuracy ranging from 89% to 98% Spravato, a new intranasal treatment for resistant depression Intended for patients who have not responded adequately to at least two different antidepressants Consider long-acting injectable antipsychotics more often in early-phase schizophrenia Study reports significant delay in time to hospitalization compared to usual care when LAIAs are used in patients with early-phase schizophrenia First Previous 32 33 34 35 36 Next Last
